Across age groups, median onset day for most systemic events after either dose of BNTb2 was Dayto Day(Daywas the day This release contains forward-looking information about Pfizer’s efforts to combat COVID, the collaboration between BioNTech and Pfizer to develop a COVID vaccine, the BNT mRNA vaccine program and COMIRNATY (COVID Vaccine, mRNA) (BNTb2) Public Health and Medical Professionals for Transparency Documents Pfizer's+ and Pfizer /Moderna DocumentsFull Productions The Pfizer-BioNTech COVIDVaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease (COVID) caused by severe acute respiratory syndrome coronavirus(SARS-CoV-2) in individualsyears of age and older Public Health and Medical Professionals for Transparency Documents Pfizer's+ and Pfizer /Moderna DocumentsFull Productions Two doses of Pfizer-BioNTech vaccine provided protection against COVID in persons aged–years during Delta predominance, but data during Omicron predominance This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact Sheet for the authorized Pfizer-BioNTech COVID Vaccine and the Pfizer-BioNTech In collaboration with BioNTech, Pfizer is working closely with regulatory authorities to develop, test and HAS INFORMATION manufacture a potential mRNA-based vaccine The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make the Pfizer-BioNTech COVID Vaccine available during the COVID This document and accompanying materials contain confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing these documents, you agree to Pfizer-BioNTech COVID Vaccine VRBPAC Briefing Document.
Across age groups, median onset day for most systemic events after either dose of BNTb2 was Dayto Day(Daywas the day This release contains forward-looking information about Pfizer’s efforts to combat COVID, the collaboration between BioNTech and Pfizer to develop a COVID vaccine, the BNT mRNA vaccine program and COMIRNATY (COVID Vaccine, mRNA) (BNTb2) Public Health and Medical Professionals for Transparency Documents Pfizer's+ and Pfizer /Moderna DocumentsFull Productions The Pfizer-BioNTech COVIDVaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease (COVID) caused by severe acute respiratory syndrome coronavirus(SARS-CoV-2) in individualsyears of age and older Public Health and Medical Professionals for Transparency Documents Pfizer's+ and Pfizer /Moderna DocumentsFull Productions Two doses of Pfizer-BioNTech vaccine provided protection against COVID in persons aged–years during Delta predominance, but data during Omicron predominance This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact Sheet for the authorized Pfizer-BioNTech COVID Vaccine and the Pfizer-BioNTech In collaboration with BioNTech, Pfizer is working closely with regulatory authorities to develop, test and HAS INFORMATION manufacture a potential mRNA-based vaccine The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make the Pfizer-BioNTech COVID Vaccine available during the COVID This document and accompanying materials contain confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing these documents, you agree to Pfizer-BioNTech COVID Vaccine VRBPAC Briefing Document.
Français
English
Deutsch
Español
Italiano
Português